keyword
MENU ▼
Read by QxMD icon Read
search

Second primary, lung cancer

keyword
https://www.readbyqxmd.com/read/28797999/long-term-results-of-post-operative-pelvic-image-guided-intensity-modulated-radiotherapy-in-gynecological-malignancies
#1
Rashi Agrawal, Sowmiya Prithiviraj, Dinesh Singh, Vaishali Zamre, Sandeep Agrawal, Arun Kumar Goel, Kanika Gupta, Bala Subramanian
OBJECTIVE: To assess late clinical outcomes with image guided intensity modulated radiotherapy (IG- IMRT) in gynecological malignancies. PATIENTS AND METHODS: We have been practicing IG IMRT for gynecological malignancies since January 2009. Here we are presenting our experience with this modern technique at median follow up of 38 months. During whole treatment bladder filling protocol was followed. Both target volumes and critical structures were contoured according to RTOG guidelines...
May 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28795361/metachronous-lung-cancer-clinical-characteristics-and-effects-of-surgical-treatment
#2
Adam Rzechonek, Piotr Błasiak, Beata Muszczyńska-Bernhard, Konrad Pawełczyk, Grzegorz Pniewski, Maciej Ornat, Jędrzej Grzegrzółka, Anna Brzecka
The occurrence of a second lung tumor after surgical removal of lung cancer usually indicates a lung cancer metastasis, but sometimes a new lesion proves to be a new primary lung cancer, i.e., metachronous lung cancer. The goal of the present study was to conduct a clinical evaluation of patients with metachronous lung cancer and lung cancer metastasis, and to compare the early and distant outcomes of surgical treatment in both cancer types. There were 26 age-matched patients with lung cancer metastases and 23 patients with metachronous lung cancers, who underwent a second lung cancer resection...
August 10, 2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28781880/acute-aortic-occlusion-due-to-tumor-embolism-in-a-patient-with-lung-malignancy
#3
Stella Lioudaki, Nikolaos Kontopodis, Stefanos Palioudakis, Anastasios V Koutsopoulos, Ioannis Drositis, Christos V Ioannou
OBJECTIVES: Acute lower limb ischemia caused by tumor embolization is rare, despite the fact that cancer is a common cause of hypercoagulability predisposing to venous thrombosis. Arterial embolization is mostly associated with intracardiac tumors while lung malignancies are the second most common cause of tumor embolism. METHODS: In this report, we present a male patient who developed acute bilateral lower limb ischemia in the immediate postoperative period after a thoracotomy for attempted left upper lobe resection for lung cancer...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28748213/metabolic-reprogramming-underlies-metastatic-potential-in-an-obesity-responsive-murine-model-of-metastatic-triple-negative-breast-cancer
#4
Ciara H O'Flanagan, Emily L Rossi, Shannon B McDonell, Xuewen Chen, Yi-Hsuan Tsai, Joel S Parker, Jerry Usary, Charles M Perou, Stephen D Hursting
The vast majority of cancer-related deaths are due to metastatic disease, whereby primary tumor cells disseminate and colonize distal sites within the body. Triple negative breast cancer typically displays aberrant Wnt signaling, lacks effective targeted therapies, and compared with other breast cancer subtypes, is more likely to recur and metastasize. We developed a Wnt-driven lung metastasis model of triple negative breast cancer (metM-Wnt(lung)) through serial passaging of our previously described, nonmetastatic, claudin-low M-Wnt cell line...
2017: NPJ Breast Cancer
https://www.readbyqxmd.com/read/28744752/radiotherapy-for-ductal-carcinoma-in-situ-and-risk-of-second-non-breast-cancers
#5
Diana R Withrow, Lindsay M Morton, Rochelle E Curtis, Sara J Schonfeld, Amy Berrington de González
PURPOSE: Radiotherapy for ductal carcinoma (DCIS) is increasing, but the risks and benefits of the treatment remain uncertain. We aimed to investigate the relationship between radiotherapy for DCIS and risk of second non-breast cancers in a large US cohort. METHODS: We conducted a retrospective cohort study of 52,556 women in 12 U.S. population-based cancer registries diagnosed with first primary DCIS during 1992-2008 at age 25-79 years. We estimated relative risks (RRs), attributable risks (AR), and excess absolute risks (EAR) of second non-breast cancers associated with radiotherapy using Poisson regression adjusted for age at year of diagnosis, grade, hormonal therapy (yes/no or unknown), and time since diagnosis...
July 25, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28739724/therapeutic-role-of-mir-140-5p-for-the-treatment-of-non-small-cell-lung-cancer
#6
Valentina Flamini, Wen G Jiang, Yuxin Cui
BACKGROUND/AIM: Lung cancer is the second most common cancer in both men and women, after prostate and breast cancer, respectively. There are two main types of primary lung cancer, non-small cell lung cancer (NSCLC), which accounts for approximately 85-90% of all lung cancer cases, and small cell lung cancer (SCLC), which accounts for the other 10-15% of lung cancers. MiRNAs are small molecules that post-transcriptionally regulate many genes and contribute to many disease aetiologies, including tumours...
August 2017: Anticancer Research
https://www.readbyqxmd.com/read/28734822/icotinib-versus-whole-brain-irradiation-in-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-multiple-brain-metastases-brain-a-multicentre-phase-3-open-label-parallel-randomised-controlled-trial
#7
Jin-Ji Yang, Caicun Zhou, Yisheng Huang, Jifeng Feng, Sun Lu, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng, Chengping Hu, Gongyan Chen, Li Zhang, Xiaoqing Liu, Hong Hong Yan, Fen Lai Tan, Wenzhao Zhong, Yi-Long Wu
BACKGROUND: For patients with non-small-cell lung cancer (NSCLC) and multiple brain metastases, whole-brain irradiation (WBI) is a standard-of-care treatment, but its effects on neurocognition are complex and concerning. We compared the efficacy of an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), icotinib, versus WBI with or without chemotherapy in a phase 3 trial of patients with EGFR-mutant NSCLC and multiple brain metastases. METHODS: We did a multicentre, open-label, parallel randomised controlled trial (BRAIN) at 17 hospitals in China...
July 19, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28730888/preoperative-exercise-training-prevents-functional-decline-after-lung-resection-surgery-a-randomized-single-blind-controlled-trial
#8
Raquel Sebio García, Maria Isabel Yáñez-Brage, Esther Giménez Moolhuyzen, Marta Salorio Riobo, Ana Lista Paz, Jose María Borro Mate
OBJECTIVES: To investigate the effects of a preoperative pulmonary rehabilitation programme in patients with lung cancer undergoing video-assisted thoracic surgery. DESIGN: Randomized, single-blind controlled trial. SETTING: Teaching hospital. SUBJECTS: Patients with suspected or confirmed lung cancer undergoing video-assisted thoracic surgery. INTERVENTION: Participants were randomized to either a prehabilitation group or a control group...
August 2017: Clinical Rehabilitation
https://www.readbyqxmd.com/read/28729154/tremelimumab-as-second-line-or-third-line-treatment-in-relapsed-malignant-mesothelioma-determine-a-multicentre-international-randomised-double-blind-placebo-controlled-phase-2b-trial
#9
Michele Maio, Arnaud Scherpereel, Luana Calabrò, Joachim Aerts, Susana Cedres Perez, Alessandra Bearz, Kristiaan Nackaerts, Dean A Fennell, Dariusz Kowalski, Anne S Tsao, Paul Taylor, Federica Grosso, Scott J Antonia, Anna K Nowak, Maria Taboada, Martina Puglisi, Paul K Stockman, Hedy L Kindler
BACKGROUND: New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma. METHODS: DETERMINE was a double-blind, placebo-controlled, phase 2b trial done at 105 study centres across 19 countries in patients with unresectable pleural or peritoneal malignant mesothelioma who had progressed after one or two previous systemic treatments for advanced disease...
July 17, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28717751/second-primary-cancers-after-primary-breast-cancer-diagnosis-in-israeli-women-1992-to-2006
#10
Barbara G Silverman, Irena Lipshitz, Lital Keinan-Boker
PURPOSE: Improvements in early detection and treatment have resulted in improved long-term survival from breast cancer, which increases the likelihood of the occurrence of second primary cancers. We calculated the risk of second primary cancers among Israeli women receiving a first primary breast cancer diagnosis. METHODS: By using data from the Israel National Cancer Registry, we identified 46,090 women with invasive breast cancer diagnosed between 1990 and 2006 and non-breast primary cancers diagnosed subsequent to breast cancer diagnosis...
April 2017: Journal of Global Oncology
https://www.readbyqxmd.com/read/28712277/moderate-hypofractionated-image-guided-thoracic-radiotherapy-for-locally-advanced-node-positive-non-small-cell-lung-cancer-patients-with-very-limited-lung-function-a-case-report
#11
Farkhad Manapov, Olarn Roengvoraphoj, Minglun Li, Chukwuka Eze
Patients with locally advanced lung cancer and very limited pulmonary function (forced expiratory volume in 1 second [FEV1] ≤ 1 L) have dismal prognosis and undergo palliative treatment or best supportive care. We describe two cases of locally advanced node-positive non-small cell lung cancer (NSCLC) patients with very limited lung function treated with induction chemotherapy and moderate hypofractionated image-guided radiotherapy (Hypo-IGRT). Hypo-IGRT was delivered to a total dose of 45 Gy to the primary tumor and involved lymph nodes...
June 2017: Radiation Oncology Journal
https://www.readbyqxmd.com/read/28709798/risk-of-second-primary-malignancies-in-patients-with-follicular-lymphoma-a-united-states-population-based-study
#12
Smith Giri, Vijaya Raj Bhatt, Vivek Verma, Ranjan Pathak, R Gregory Bociek, Julie M Vose, James O Armitage
BACKGROUND: With the improving outcomes of patients with follicular lymphoma (FL), it is imperative to focus on survivorship issues, including the development of second primary malignancies (SPMs). We used a large US database to measure the risk of SPMs among FL survivors. MATERIALS AND METHODS: We used the Surveillance, Epidemiology, and End Results-13 registry to identify FL patients from 1992 to 2011. We calculated the risk of SPMs, developing ≥ 6 months after diagnosis, using the standardized incidence ratio (SIR) and absolute excess risk...
June 24, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28705024/medi-4736-durvalumab-in-non-small-cell-lung-cancer
#13
Arnaud Jeanson, Fabrice Barlesi
Immune checkpoint inhibitors (ICI) are now a therapeutic option for advanced non-small cell lung cancer (NSCLC) patients. ICI, such as the PD-1 inhibitors nivolumab and pembrolizumab and the PD-L1 inhibitor atezolizumab, have already been marketed for the treatment of pretreated patients with advanced NSCLC. Other notable PD-L1 inhibitors under development include avelumab and durvalumab. Areas covered: This article reviews literature on durvalumab development, from the preclinical data to the results of phase III clinical trials, whether published or presented at international scientific conferences...
July 13, 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28684658/the-efficacy-of-40-mg-versus-dose-de-escalation-to-less-than-40-mg-of-afatinib-giotrif-as-the-first-line-therapy-for-patients-with-primary-lung-adenocarcinoma-harboring-favorable-epidermal-growth-factor-mutations
#14
Chien-Ying Liu, Cheng-Ta Yang, Chih-Liang Wang, Shih-Hong Li, Ping-Chih Hsu, Chih-Hung Chen, Ting-Yu Lin, Chih-Hsi Kuo, Yueh-Fu Fang, How-Wen Ko, Chih-Teng Yu, Tai-Yun Yang
The choice of a first-line therapy for lung cancer is a crucial decision that can impact the survival as well as the quality of life of a patient. Inhibitors of epidermal growth factor receptor (EGFR) such as afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell lung cancer harboring favorable EGFR mutations. Although afatinib has greater efficacy than other EGFR inhibitors, adverse events related to its use can result in the discontinuation of the therapy. In this study, we compared the therapeutic efficacy in lung cancer patients of a regimen of 40 mg/day of afatinib with that of a lower dose regimen of <40 mg/day resulting either from a lower starting dose of 30 mg/day or dose adjustment...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28680772/first-clinical-report-on-comparative-treatment-and-survival-outcomes-in-second-cancers-after-primary-head-and-neck-cancer-a-population-based-study
#15
Xin Wang, Elizabeth A Mauer, Paul Christos, Julia Manzerova, A Gabriella Wernicke, Bhupesh Parashar
INTRODUCTION: To compare patients' survival of second primary malignancy (SPM) after head and neck squamous cell carcinoma (HNSCC). METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was utilized (1973-2011). The Kaplan-Meier method with log-rank test was used to compare the overall survival (OS) and cause-specific survival (CSS) among treatment methods from the time of diagnosis of SPMs. Cox proportional regression models were used to adjust the impact for risk factors on CSS...
May 29, 2017: Curēus
https://www.readbyqxmd.com/read/28679770/therapy-of-small-cell-lung-cancer-sclc-with-a-topoisomerase-i-inhibiting-antibody-drug-conjugate-adc-targeting-trop-2-sacituzumab-govitecan
#16
Jhanelle E Gray, Rebecca S Heist, Alexander N Starodub, D Ross Camidge, Ebenezer A Kio, Gregory A Masters, W Thomas Purcell, Michael J Guarino, Jamal Misleh, Charles J Schneider, Bryan J Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A Messersmith, Serengulam V Govindan, Pius P Maliakal, Boyd Mudenda, William A Wegener, Robert M Sharkey, David M Goldenberg
Purpose: We evaluated a Trop-2-targeting antibody conjugated with SN-38 in metastatic small-cell lung cancer (mSCLC) patients. <p>Experimental Design: Sacituzumab govitecan was studied in patients with pretreated (median, 2; range, 1-7) mSCLC who received either 8 or 10 mg/kg i.v. on days 1 and 8 of 21-day cycles. The primary endpoints were safety and objective response rate (ORR); duration of response, progression-free survival (PFS), and overall survival (OS) were secondary endpoints.</p> <p>Results: Sixty percent of patients showed tumor shrinkage from baseline CTs...
July 5, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28678671/temporal-subtraction-of-serial-ct-images-with-large-deformation-diffeomorphic-metric-mapping-in-the-identification-of-bone-metastases
#17
Ryo Sakamoto, Masahiro Yakami, Koji Fujimoto, Keita Nakagomi, Takeshi Kubo, Yutaka Emoto, Thai Akasaka, Gakuto Aoyama, Hiroyuki Yamamoto, Michael I Miller, Susumu Mori, Kaori Togashi
Purpose To determine the improvement of radiologist efficiency and performance in the detection of bone metastases at serial follow-up computed tomography (CT) by using a temporal subtraction (TS) technique based on an advanced nonrigid image registration algorithm. Materials and Methods This retrospective study was approved by the institutional review board, and informed consent was waived. CT image pairs (previous and current scans of the torso) in 60 patients with cancer (primary lesion location: prostate, n = 14; breast, n = 16; lung, n = 20; liver, n = 10) were included...
July 3, 2017: Radiology
https://www.readbyqxmd.com/read/28672103/shingosine-1-phosphate-suppresses-chondrosarcoma-metastasis-by-up-regulation-of-tissue-inhibitor-of-metalloproteinase-3-through-suppressing-mir-101-expression
#18
Chun-Hao Tsai, Dong-Ying Yang, Chih-Yang Lin, Tsung-Ming Chen, Chih-Hsin Tang, Yuan-Li Huang
Chondrosarcoma is the second most common primary malignancy form of bone cancer, exhibiting resistance to chemotherapy and radiation therapy as well as developing high metastasis ability in late stage tumors. Thus, understanding the metastatic processes of chondrosarcoma is considered a strategy for treatment of this disease. Sphingosine 1-phosphate (S1P), a bioactive sphingolipid, is produced intracellularly by sphingosine kinase (SphK) and is regarded as a second signaling molecule that regulates inflammation, proliferation, angiogenesis, and metastasis...
July 3, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28644772/risk-stratification-for-second-primary-lung-cancer
#19
Summer S Han, Gabriel A Rivera, Martin C Tammemägi, Sylvia K Plevritis, Scarlett L Gomez, Iona Cheng, Heather A Wakelee
Purpose This study estimated the 10-year risk of developing second primary lung cancer (SPLC) among survivors of initial primary lung cancer (IPLC) and evaluated the clinical utility of the risk prediction model for selecting eligibility criteria for screening. Methods SEER data were used to identify a population-based cohort of 20,032 participants diagnosed with IPLC between 1988 and 2003 and who survived ≥ 5 years after the initial diagnosis. We used a proportional subdistribution hazards model to estimate the 10-year risk of developing SPLC among survivors of lung cancer LC in the presence of competing risks...
June 23, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28633674/primary-tumor-volume-delineation-in-head-and-neck-cancer-missing-the-tip-of-the-iceberg
#20
Olgun Elicin, Dario Terribilini, Mohamed Shelan, Werner Volken, Etienne Mathier, Alan Dal Pra, Daniel M Aebersold, Michael K Fix, Peter Manser
BACKGROUND: The aim was to evaluate the geometric and corresponding dosimetric differences between two delineation strategies for head and neck tumors neighboring air cavities. METHODS: Primary gross and clinical tumor volumes (GTV and CTV) of 14 patients with oropharynx or larynx tumors were contoured using a soft tissue window (S). In a second strategy, the same volumes were contoured with an extension to include the parts which became visible on lung window (L)...
June 20, 2017: Radiation Oncology
keyword
keyword
89877
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"